Gilead Sciences’ Kite Pharma Announces Workforce Reduction and Strategy Shift Amid FDA Review
November 29, 2023
Gilead Sciences’ Kite Pharma is reducing its workforce by approximately 7% as part of a business strategy revision. The restructuring focuses on aligning with strategic priorities, leading to team reorganizations and eliminating roles not aligned with these goals. Despite creating around 90 new positions, the net workforce reduction is about 5%. The changes mainly affect the U.S. staff. Kite’s leader, Cindy Perettie, has communicated support for those impacted in finding new roles within the company. This comes amidst an FDA review of Kite’s CAR-T therapies, Yescarta and Tecartus, due to secondary cancer concerns.
To read more, click here.
[Source: Fierce Pharma, November 29th, 2023]
